This Article Full Text (PDF) Other Versions of this Article: AAC.01583-06v1 51/7/2656    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Freifeld, A. Articles by Connolly, P. Search for Related Content PubMed PubMed Citation Articles by Freifeld, A. Articles by Connolly, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2656-2657, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.01583-06

LETTERS TO THE EDITOR

Relationship of Blood Level and Susceptibility in Voriconazole Treatment of Histoplasmosis

	LETTER

Top LETTER REFERENCES

Serum specimens from nine patients with disseminated histoplasmosis that had been submitted for antigen testing were later tested for serum levels of voriconazole (3). All nine patients were considered to have improved clinically during secondary oral voriconazole treatment at a dose of 200 mg twice daily. All patients had received voriconazole for at least 2 weeks before blood concentrations were determined, but the exact timing of the blood specimens obtained following the oral administration of voriconazole was not recorded. Specimens had been frozen for up to 4 years prior to the determination of serum drug levels. Our experience with a similar compound, itraconazole, showed no loss of activity after 4 years at –20°C. Furthermore, the levels observed in the patients in this study are consistent with levels obtained in real-time testing of fresh specimens. Isolates of H. capsulatum for this patient cohort were unavailable for voriconazole susceptibility testing; therefore, archived H. capsulatum isolates from AIDS patients who had either primary or relapsed histoplasmosis were employed for this testing by a modified CLSI (formerly NCCLS) method as described previously (1). A comparison of voriconazole susceptibilities (by MIC measurements) of these archived H. capsulatum isolates from patients with both primary and relapsed disease (Fig. 1) was made with the random voriconazole blood levels measured from the nine patients who were being treated with the drug for disseminated histoplasmosis (Fig. 1).

View larger version (13K): [in this window] [in a new window]   FIG. 1. Comparison of antifungal susceptibilities of primary and relapse isolates of H. capsulatum to voriconazole and random voriconazole blood levels in patients receiving voriconazole for the treatment of histoplasmosis. The left-hand axis depicts the MIC scale for the primary and relapse isolates, included in the left-hand section of the figure. The median MIC was 0.015 µg/ml for the primary and 0.030 µg/ml for the relapse isolates. The right-hand axis depicts voriconazole blood levels for the histoplasmosis cases, included in the right-hand section of the figure. The three specimens with blood levels shown below the 0.125-µg/ml voriconazole blood level designation demonstrated a zone of inhibition in the bioassay, which was below the lowest standard. None Detected, no inhibition was observed for the specimen.

Pascual et al. reported a 90% response for patients with aspergillosis or candidiasis with voriconazole trough levels of >1.0 mg/ml and only a 54% response for patients with lower troughs (6). Smith et al. reported findings for 28 patients with invasive mycoses, mostly aspergillosis, and observed favorable responses for 100% (10/10) of patients with random serum levels, >2.05 µg/ml, compared with unfavorable responses for 44% of patients with lower concentrations (9). Among our nine patients with histoplasmosis, random levels were <2.05 µg/ml in 60%, <1.0 µg/ml in 45%, and <0.125 µg/ml in 30%. Although we cannot establish a "subtherapeutic level" from our cases, since all appear to have responded to the therapies given, we suggest that levels that measure below the calibrator level of 0.125 µg/ml might be considered subtherapeutic. This task is further complicated by the paucity of voriconazole MIC data for histoplasmosis. Given the variability in serum levels in patients receiving voriconazole for histoplasmosis, the relatively high MIC₉₀ of voriconazole for H. capsulatum noted herein, and the lack of prospective trials establishing the effectiveness of voriconazole for the treatment of histoplasmosis, we suggest that it may be prudent to measure trough concentrations of voriconazole in patients receiving it for treatment of histoplasmosis to ensure detectable drug levels.

	FOOTNOTES

 
Published ahead of print on 16 April 2007.

	REFERENCES

Top LETTER REFERENCES

 

1. Connolly, P., J. Wheat, C. Schnizlein-Bick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Bridendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43:322-328.[Abstract/Free Full Text]
2. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.[CrossRef][Medline]
3. Freifeld, A. G., P. C. Iwen, B. L. Lesiak, R. K. Gilroy, R. B. Stevens, and A. C. Kalil. 2005. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl. Infect. Dis. 7:109-115.[CrossRef][Medline]
4. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.[Abstract]
5. Leveque, D., Y. Nivoix, F. Jehl, and R. Herbrecht. 2006. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents 27:274-284.[CrossRef][Medline]
6. Pascual, A. A., S. Bolay, and O. Marchetti. 2006. Documentation of low voriconazole blood levels followed by dose adjustment in patients with invasive fungal infections not responding to therapy, abstr. M-1304. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006.
7. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1):10-16.[CrossRef][Medline]
8. Purkins, L., N. Wood, K. Greenhalgh, M. D. Eve, S. D. Oliver, and D. Nichols. 2003. The pharmacokinetics and safety of intravenous voriconazole—a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl. 1):2-9.[CrossRef][Medline]
9. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.[Abstract/Free Full Text]
10. Trifilio, S., R. Ortiz, G. Pennick, A. Verma, J. Pi, V. Stosor, T. Zembower, and J. Mehta. 2005. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35:509-513.[CrossRef][Medline]

This Article Full Text (PDF) Other Versions of this Article: AAC.01583-06v1 51/7/2656    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Freifeld, A. Articles by Connolly, P. Search for Related Content PubMed PubMed Citation Articles by Freifeld, A. Articles by Connolly, P.